Nuvalent, Inc. (NUVL) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $123.96 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Nov 17, 2025 | Etzer Darout | Barclays | $152.00 | +22.6% |
| Oct 31, 2025 | David Dai | UBS | $132.00 | +6.5% |
| Oct 27, 2025 | Kelsey Goodwin | Piper Sandler | $128.00 | +3.3% |
| Oct 15, 2025 | Josh Schimmer | Cantor Fitzgerald | $135.00 | +8.9% |
| Jun 24, 2025 | Swayampakula Ramakanth | H.C. Wainwright | $130.00 | +4.9% |
| Nov 13, 2024 | Etzer Darout | BMO Capital | $134.00 | +8.1% |
| Oct 24, 2024 | David Dai | UBS | $100.00 | -19.3% |
| Sep 16, 2024 | Kelsey Goodwin | Guggenheim | $105.00 | -15.3% |
| Sep 16, 2024 | Bradley Canino | Stifel Nicolaus | $135.00 | +8.9% |
| Sep 16, 2024 | Christopher Raymond | Raymond James | $100.00 | -19.3% |
| Jul 10, 2024 | Bradley Canino | Stifel Nicolaus | $115.00 | -7.2% |
| Apr 17, 2024 | Roger Song | Jefferies | $97.00 | -21.7% |
| Apr 1, 2024 | Christopher Liu | Leerink Partners | $110.00 | -11.3% |
Top Analysts Covering NUVL
NUVL vs Sector & Market
| Metric | NUVL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.75 | 2.25 | 2.42 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +2.7% | +16316.2% | +17.1% |
| P/E Ratio | -18.00 | 3.03 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $3M | $3M | $3M | 2 |
| 2026-12-31 | $12M | $12M | $12M | 2 |
| 2027-03-31 | $78M | $78M | $78M | 2 |
| 2027-06-30 | $19M | $19M | $19M | 2 |
| 2027-09-30 | $28M | $28M | $28M | 2 |
| 2027-12-31 | $48M | $48M | $48M | 2 |
| 2028-12-31 | $517M | $517M | $517M | 14 |
| 2029-12-31 | $359M | $905M | $1.61B | 9 |
| 2030-12-31 | $482M | $1.22B | $2.16B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.41 | $-1.41 | $-1.41 | 4 |
| 2026-12-31 | $-1.36 | $-1.36 | $-1.36 | 4 |
| 2027-03-31 | $-0.52 | $-0.52 | $-0.52 | 4 |
| 2027-06-30 | $-1.31 | $-1.31 | $-1.31 | 4 |
| 2027-09-30 | $-1.17 | $-1.17 | $-1.17 | 4 |
| 2027-12-31 | $-0.90 | $-0.90 | $-0.90 | 4 |
| 2028-12-31 | $-4.49 | $-1.01 | $2.96 | 13 |
| 2029-12-31 | $0.65 | $2.99 | $6.01 | 11 |
| 2030-12-31 | $1.10 | $5.08 | $10.19 | 5 |
Frequently Asked Questions
What is the analyst consensus for NUVL?
The consensus among 16 analysts covering Nuvalent, Inc. (NUVL) is Hold with an average price target of $127.32.
What is the highest price target for NUVL?
The highest price target for NUVL is $152.00, set by Etzer Darout at Barclays on 2025-11-17.
What is the lowest price target for NUVL?
The lowest price target for NUVL is $97.00, set by Roger Song at Jefferies on 2024-04-17.
How many analysts cover NUVL?
16 analysts have issued ratings for Nuvalent, Inc. in the past 12 months.
Is NUVL a buy or sell right now?
Based on 16 analyst ratings, NUVL has a consensus rating of Hold (2.75/5) with a +2.7% upside to the consensus target of $127.32.
What are the earnings estimates for NUVL?
Analysts estimate NUVL will report EPS of $-1.41 for the period ending 2026-09-30, with revenue estimated at $3M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.